Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

Somai expands Cookies partnership to include Europe and the UK

SOMAÍ Group and its subsidiary, RPK Biopharma expanded their existing partnership with Cookies Creative Consulting & Promotions, Inc., (CCC&P) to include additional territories for the dried flower portfolio and manufacture different extract products. The amendment enables SOMAÍ to exclusively cultivate, manufacture, and distribute Cookies branded products through its distribution partners in UK, Germany, Portugal, Poland, Malta, and the Czech Republic.

Cookies has a diverse portfolio, including over 70 proprietary cannabis cultivars and more than 2,000 products that Cookies has developed over the years.

Under the terms of the agreement, SOMAÍ's subsidiary RPK Biopharma will cultivate Cookies licensed genetics at their large scale state-of-the-art indoor cultivation facilities located in Portugal, to be later distributed through its partners in Germany, the UK, Portugal, Poland, Malta, and the Czech Republic. SOMAÍ will also leverage RPK Biopharma's vast EU-GMP processing capabilities to serve as a hub for importing Cookies branded products from around the world. Furthermore, SOMAÍ's medical subsidiary SOMAÍ Pharmaceuticals will utilize its cutting-edge EU-GMP manufacturing capabilities to transform Cookies Flower into a range of next-generation products tailored to meet the evolving demands of patients, ranging from oral drops and soft gel capsules to vape oils and gummies. Combined with market-leading and innovative Cookies' genetics, RPK's premium cultivation proficiency, and SOMAÍ's groundbreaking manufacturing expertise, companies are poised to deliver premium cannabinoid therapeutics that excel at the standards of excellence within the largest and fastest-growing international markets.

Michael Sassano, the Founder and Interim CEO of SOMAÍ Group, said: "SOMAÍ's 86+ stabilized extract portfolio just got bigger by bringing the next generation of Cookie's branded extract portfolio, which includes Cookie's oral drop series, vape series, gel cap series, and edible series, to be launched in July for Europe and the UK. Making an EU-GMP product line of extracts for Cookies is a global product that we hope to bring to more and more countries as they allow cannabis extracts."

Tom Flow, Managing Director of RPK Biopharma, said: "Working with Berner, Parker, and their team to bring Cookies to both the German and UK market is a huge milestone for RPK Biopharma and also signifies the deep commitment we have to produce the very best cannabis flower and products. The European cannabis market is at a tipping point with Germany having just announced decriminalization of cannabis. We're excited to bring one of the best-known cannabis brands in the world to patients across Europe, the UK, and beyond."

Gilbert Milam Jr. (Berner), co-founder and CEO of Cookies: "Germany is an exciting market for me for multiple reasons, the energy and vibe around legalization is contagious and is opening the doors for Europe. Also in the early 2000's I had my music randomly break on a radio station Jam Fm and took a trip to Germany and experienced the culture 1st hand in my early 20's. The UK has been fascinated with California cannabis and helped build the hype on some of the biggest strains in the USA. This partnership is about to be a powerful one, and I can't express how ready I am to share our genetics with Europe," said Berner, Co-Founder and CEO of Cookies.

For more information:
Somai Pharmaceuticals


Publication date: